Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. (CATX) Financial Performance & Income Statement Overview
Explore the financials of Perspective Therapeutics, Inc. (CATX), including yearly and quarterly data on income, cash flow, and balance sheets.
Perspective Therapeutics, Inc. (CATX) Income Statement & Financial Overview
Analyze Perspective Therapeutics, Inc.’s CATX earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q3 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $12.88M | $12.03M | $12.03M | $9.28M |
| SG&A Expenses | $8.25M | $6.97M | $6.97M | $5.51M |
| Operating Expenses | $46.44M | $18.63M | $18.63M | $14.26M |
| Total Costs & Expenses | $45.22M | $18.63M | $18.63M | $14.26M |
| Interest Income | $2.65M | $3.58M | $3.58M | $3.08M |
| Interest Expense | -$73000.00 | $69000.00 | $69000.00 | $23000.00 |
| Depreciation & Amortization | $721000.00 | $669000.00 | $669000.00 | $570000.00 |
| EBITDA | -$43.96M | -$14.38M | -$14.38M | -$10.68M |
| EBITDA Ratio | $0.00 | $0.00 | ||
| Operating Income | -$44.98M | -$18.63M | -$18.63M | -$14.26M |
| Operating Income Ratio | $0.00 | $0.00 | ||
| Other Income/Expenses (Net) | $2.72M | $3.51M | $3.51M | $2.99M |
| Income Before Tax | -$42.27M | -$15.12M | -$15.12M | -$11.28M |
| Income Before Tax Ratio | $0.00 | $0.00 | ||
| Income Tax Expense | -$2.10M | $0.00 | $0.00 | -$61000.00 |
| Net Income | -$40.17M | -$15.12M | -$15.12M | -$11.70M |
| Net Income Ratio | $0.00 | $0.00 | ||
| EPS | -$0.57 | -$0.21 | -$0.21 | -$0.18 |
| Diluted EPS | -$0.57 | -$0.21 | -$0.21 | -$0.18 |
| Weighted Avg Shares Outstanding | $70.63M | $70.63M | $70.63M | $66.65M |
| Weighted Avg Shares Outstanding (Diluted) | $70.63M | $70.63M | $70.63M | $66.65M |
Financial performance has remained strong, with revenue growing from $0.00 in Q4 2023 to $0.00 in Q4 2024. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$44.98M in Q4 2024, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$43.96M. Net income dropped to -$40.17M, keeping EPS at -$0.57. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan